Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-Aza-2′-deoxycytidine

Molecular Pharmacology

Volumn 59, Issue 4, 2001, Pages 751-757

  Karpf, Adam R ^a   Moore, Brent C ^a   Ririe, Ted O ^a   Jones, David A ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE; METHYLTRANSFERASE INHIBITOR; PROTEIN P21; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; DNA ADDUCT; DNA DAMAGE; DNA METHYLATION; DRUG INDICATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA; PRIORITY JOURNAL; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SOLID TUMOR; TUMOR SUPPRESSOR GENE;

EID: 0035057219     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.59.4.751     Document Type: Review

References (36)

1. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines
2. DNA methylation as a target for drug design
3. The relationship of DNA methylation to cancer
4. Requirement for p53 and p21 to sustain G2 arrest after DNA damage
5. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
6. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis
7. Role of estrogen receptor gene demethylation and DNA methyltransferase. DNA adduct formation in 5-aza-2′deoxycytidine-induced cytotoxicity in human breast cancer cells
8. Down-regulation of human DNA-(cytosine-5) methyltransferase induces cell cycle regulators p16(ink4A) and p21(WAF/Cip1) by distinct mechanisms
9. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing
10. Rapid colorimetric assay for cell viability: Application to the quantitation of cytotoxic and growth inhibitory lymphokines
11. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
12. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation
13. Decitabine studies in chronic and acute myelogenous leukemia
14. Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells
15. Loss of p73 gene expression in leukemias/lymphomas, due to hypermethylation
16. Accumulating active p53 in the nucleus by inhibition of nuclear export: A novel strategy to promote the p53 tumor suppressor function
17. Suppression of intestinal neoplasia by DNA hypomethylation
18. Regulation of p53 in response to DNA damage
19. The nuclear import of p53 is determined by the presence of a basic domain and its relative position to the nuclear localization signal
20. DNA Methyltransferase Inhibition Induces the Transcription of the Tumor Suppressor p21(WAF1/CIP1/sdi1)
21. Molecular, cellular and animal pharmacology of 5-aza-2′-deoxycytidine
22. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer
23. Proteolytic cleavage of p53: A model for the activation of p53 in response to DNA damage
24. Induced N- and C-terminal cleavage of p53: A core fragment of p53, generated by interaction with damaged DNA, promotes cleavage of the N- terminus of full-length p53, whereas ssDNA induces C-terminal cleavage of p53
25. Molecular alterations in the TP53 gene of peripheral blood cells of patients with chronic myeloid leukemia
26. Single-site methylation within the p53 promoter region reduces gene expression in a reporter gene construct: Possible in vivo relevance during tumorigenesis
27. Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide
28. Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients
29. Decitabine 5-Aza-2′-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: Preliminary observations
30. A phase II study of 5-aza-2′deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer
31. p21WAP1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis
32. p21 is necessary for the p53-mediated G1 arrest in human cancer cells
33. Interleukin (IL)-10 inhibits nuclear factor κB (NF κB) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms
34. Detection of p53 gene mutations in human leukemia by PCR-SSCP analysis and direct nucleotide sequencing
35. Low-dose 5-Aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients
36. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas